300887 Pony Testing International Group
- 9.77
- +0.01+0.10%
Pony Testing International Group News
Penile test (300887.SZ): Currently no biosynthesis business
Gelonghui, May 8 | Puni Test (300887.SZ) said on the investor interactive platform that Hubei Zhongjia Synthetic Pharmaceutical Co., Ltd. has a GMP production system and production capacity for APIs, and is the “last mile” to open up a one-stop biomedical technology platform for the company. At this point, the Penney Group can provide full-process technical support for biomedical research and development. Currently, there is no biosynthesis business.
Penney Test (300887): Revenue performance is under pressure and waiting for demand to be released
Core view: Revenue performance in '23 and 24Q1 is under pressure, waiting for demand to be released. The company released the 2023 annual report and the 2024 quarterly report: the company achieved revenue of 2,468 billion yuan in 2023 (year-on-year - 34.4
Penney Test (300887) Company Dynamics Research: Performance is under pressure in the short term; waiting for an upward inflection point
Event: Penney Test releases 2023 and 2024Q1 results: In 2023, the company achieved operating income of 2,468 billion yuan, a year-on-year decrease of 34.41%; realized net profit to mother of 108 million yuan, a year-on-year decrease of 6 million yuan
Penney Test (300887): Short-term medical tests affect performance growth, waiting for net interest rate to be repaired
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved net profit of 108 million yuan, a year-on-year decrease of 67%, and the performance was close to the median forecast. 2024 Q1 Company Achievement
Dongwu Securities released a research report on April 26 stating that it gave the Penney Test (300887.SZ) an increase in holdings rating. The main reasons for the rating include: 1) Affected by the medical sector, the short-term pressure on the growth rat
Dongwu Securities released a research report on April 26 stating that it gave the Penney Test (300887.SZ) an increase in holdings rating. The main reasons for the rating include: 1) Affected by the medical sector, the short-term pressure on the growth rate of performance; 2) gross margin was gradually restored, and the cost ratio returned to normal during the period; 3) endogenous and extrinsic expansion was carried out in combination, which is optimistic about the development prospects of leading testing companies. (Mainichi Keizai Shimbun)
Penney Test (300887) 2023 Report & 2024Q1 Quarterly Report Review: One-off impairment affects profit and expects profit recovery in 2024
Description of the event Penney Test releases its 2023 annual report and 2024Q1 quarterly report. In 2023, the company achieved revenue of 2,468 billion yuan, a year-on-year decrease of 34.41%; net profit to mother was 108 million yuan, a year-on-year decrease of 66.58 million yuan
Penney Test (300887): Impairment affects short-term performance and continues to build barriers to mergers and acquisitions
Introduction to this report: The company estimates that more than 140 million yuan of impairment will affect its 2023 performance, and subsequent impairment will have limited impact; the company will improve its performance structure through continuous mergers and acquisitions and build barriers to scale and management capacity, and the 2024 performance is expected to gradually increase
Penney Test (300887): 1Q24 performance under pressure, expectations for improved management to drive higher profit margins
2023 and 1Q24 results are lower than our expectations. The company announced 2023 and 1Q24 results: 2023 revenue of $2,468 billion, YoY -4.4%, net profit to mother of $108 million, YoY
Penney Test (300887): Performance continues to be under pressure, awaiting an upward inflection point in revenue
Net profit to mother in 2023 was -67% year over year, profit forecast was lowered and the target price was tested to release annual and quarterly reports. In 2023, revenue of 2.47 billion yuan (-34% YoY) was achieved, and net profit to mother was 108 million yuan (YoY)
Express News | Penney Biomedicine and Shanghai Pharmaceutical Research Institute of the Chinese Academy of Sciences launch artificial intelligence target prediction and virtual screening project
Penney Test (300887.SZ): Net loss of 97.979 million yuan in the first quarter turned into a year-on-year loss
On April 22, GLONGHUI (300887.SZ) released its first quarter report. Operating income was 334 million yuan, down 36.36% year on year, net loss of 97.979 million yuan, year-on-year loss after deducting non-net loss of 100 million yuan, year-on-year conversion loss, and basic earnings per share -0.1,794 yuan.
Penney Test (300887.SZ) announced its 2023 annual results, with net profit of 108 million yuan, a decrease of 66.58%
According to the Zhitong Finance App, Penney Test (300887.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 2,468 billion yuan, a year-on-year decrease of 34.41%. Achieved net profit attributable to shareholders of listed companies of 108 million yuan, a year-on-year decrease of 66.58%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 84.017,300 yuan, a year-on-year decrease of 69.52%. Basic earnings per share were $0.1974. It is proposed to distribute a cash dividend of 0.6 yuan (tax included) for every 10 shares to all shareholders.
Fangzheng Securities: Demand for testing services expands and the low-altitude economy is expected to contribute to new growth
Economic and social development has led to an expansion in demand for testing services, the policy side is gradually liberalizing the scope of third-party testing services, and the logic of sustainable industry growth continues to be interpreted.
Express News | Fangzheng Securities: The testing industry is expected to achieve sustainable growth
The concept of low-altitude economy began to rise. Suzhou Jiaotong Technology rose and stopped 20CM, Wanan Technology rose and stopped, Yibo Technology surged 12%, Sai Wei Smart rose more than 11%, and Baoli International, Jindun Co., Ltd., Jiechuang Inte
The concept of low-altitude economy began to rise. Suzhou Jiaotong Technology rose and stopped 20CM, Wanan Technology rose and stopped, Yibo Technology surged 12%, Sai Wei Smart rose more than 11%, and Baoli International, Jindun Co., Ltd., Jiechuang Intelligence, and Puni Test rose one after another.
Express News | Penney test: won the bid again for the 2024 National Marine Environmental Quality Multi-voyage Monitoring Project
The A-share CRO concept boosted the Penney test by nearly 5%
Glonghui, April 11 | Penicillin tests rose nearly 5%, followed by Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech.
Penile testing (300887.SZ): Currently, radiological monitoring related business accounts for relatively little
On April 8, GLONGHUI stated on the investor interactive platform that the company has the ability to monitor radioactivity in seawater, sediments and organisms, marine aquatic products, food, drinking water, minerals, cosmetic ingredients and finished products. Currently, radiation monitoring accounts for relatively little business.
Express News | Punic testing: companies can test red yeast components in pharmaceuticals
Good news about the low-altitude economy continues, and this link is expected to take the lead in benefiting
① On March 29, Sun Wensheng, deputy director of the General Department of the Civil Aviation Administration, stated that the “Interim Regulations on the Administration of Unmanned Aircraft Flight” will be implemented to improve and improve the functions of the comprehensive management platform for unmanned aerial vehicles. ② With the development of the low-altitude economy, more and more drone models are being designed and manufactured. Orders approved for airworthiness will be earlier than orders for complete machines and parts. As the speed of airworthiness certification accelerates, it will benefit the development of airworthiness testing companies.
Analysis
Price Target
No Data
